...
首页> 外文期刊>Regulatory Toxicology and Pharmacology: RTP >Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling.
【24h】

Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling.

机译:使用基于生理学的药代动力学模型评估异速生长结垢性能的剂量依赖性。

获取原文
获取原文并翻译 | 示例
           

摘要

The performance of allometric scaling of dose as a power of body weight under a variety of extrapolation conditions with respect to species, route, exposure intensity, and mechanism/mode of action, remains untested in many cases. In this paper, animal-human internal dose ratio comparisons have been developed for 12 chemicals (benzene, carbon tetrachloride, chloroform, diisopropylfluorophosphate, ethanol, ethylene oxide, methylene chloride, methylmercury, styrene, tetrachloroethene, trichloroethene, and vinyl chloride). This group of predominantly volatile and lipophilic chemicals was selected on the basis that their kinetics have been well-studied and can be predicted in mice, rats, and humans using physiologically based pharmacokinetic (PBPK) models. PBPK model predictions were compared to the allometric scaling predictions for interspecies extrapolation. Recommendations for the application of the allometric scaling are made with reference to internal dose measure (mode of action) and concentration level. The results of this assessment generally support the use of scaling factors recommended in the published literature, which includes scaling factors of 1.0 for risk assessments in which toxicity is attributed to the parent chemical or stable metabolite, and -0.75 for dose-response assessments in which toxicity is attributed to the formation of a reactive metabolite from an inhaled compound. A scaling factor of 0.75 is recommended for dose-response assessments of orally administered compounds in which toxicity is attributed to the parent chemical or stable metabolite and 1.0 for risk assessments in which toxicity is attributed to the formation of a reactive metabolite from a compound administered by the oral route. A dose-dependency in the results suggests that the scaling factors appropriate at high exposures may differ from those at low exposures, primarily due to the impact of saturable metabolism.
机译:在许多外推条件下,就物种,途径,接触强度和作用机理/作用方式而言,按重量衡量体重的权重换算性能尚未得到测试。本文针对12种化学品(苯,四氯化碳,氯仿,二异丙基氟磷酸盐,乙醇,环氧乙烷,二氯甲烷,甲基汞,苯乙烯,四氯乙烯,三氯乙烯和氯乙烯)开发了动物-人内部剂量比的比较方法。选择这组主要是挥发性和亲脂性的化学品是基于对它们的动力学进行了充分研究,并且可以使用基于生理学的药代动力学(PBPK)模型在小鼠,大鼠和人类中进行预测。将PBPK模型预测与异形缩放预测进行种间推断。参照内部剂量测量(作用方式)和浓度水平,提出了应用异度缩放的建议。该评估的结果总体上支持使用已发表文献中推荐的比例因子,其中比例因子1.0用于风险评估,其中毒性归因于母体化学物质或稳定代谢产物; -0.75用于剂量反应评估,其中毒性归因于吸入化合物形成的反应性代谢产物。对于口服给药的化合物,其毒性归因于母体化学或稳定代谢产物,建议剂量比例评估为0.75,对于风险评估的毒性归因于通过下列方式给药的化合物形成反应性代谢产物,推荐比例因子为1.0。口头途径。结果的剂量依赖性表明,高暴露量适合的比例因子可能与低暴露量不同,这主要是由于饱和代谢的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号